Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Freenome, Inc. (FRNM)

Freenome launches SimpleScreen Lung test and joint lung and colorectal blood screening

Neutral Impact 2 of 5 product/contract Written later

Freenome announced on October 20, 2026 the launch of SimpleScreen Lung, a laboratory-developed lung cancer blood test, and an offering that lets eligible patients be screened for lung and colorectal cancer through a single blood draw. The filing reports clinical validation data but no financial results, guidance, or financial terms, so the announcement gives shareholders no direct read on revenue or profit.

Key points

  • SimpleScreen Lung showed 85% sensitivity at 50% specificity and a 99.8% negative predictive value in an independent cohort of 172 lung cancer cases and 436 controls.
  • SimpleScreen Lung has not been reviewed or cleared or approved by the FDA; the SimpleScreen CRC test is FDA-approved for adults 45 and older at average risk.
  • Abbott has exclusive U.S. commercial rights to SimpleScreen CRC when it is ordered as a standalone test.
  • The launch was announced October 20, 2026, and the company will show the portfolio at the FMX conference in Nashville, October 20 to 24.

The filing

CompanyFreenome, Inc. (FRNM)
Form8-K, current report
Filed with the SECOct 20, 2026, 8:53 AM ET
Accession number0001140361-26-040186

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.